The markets closed sharply higher with the Dow leaping 256 points to 18,589 with investors cautiously optimistic about a Trump presidency. Nasdaq soared 57 points to 5,251.
On the upside
Sucampo Pharmaceuticals (Nasdaq: SCMP) reported higher third quarter earnings and revenue that beat expectations.
FibroGen (Nasdaq: FGEN) narrowed third quarter losses as revenue soared.
Ionis Pharmaceuticals (NYSE: IONS) swung to a profit for the third quarter as revenue more than doubled.
On the downside
The Food and Drug Administration has placed a clinical hold on Arrowhead Pharmaceuticals' (Nasdaq: ARWR) Heparc-2004 clinical study of ARC-520.
Concerns that president elect Donald Trump will repeal the Affordable Care Act sent shares of Centene (NYSE: CNC) plummeting.
Fears of restrictive gun regulations eased with a Trump victory sending shares of Smith & Wesson (Nasdaq: SWHC) lower.
In the broad market, advancing issues outpaced decliners by a margin of nearly 5 to 4 on the NYSE and by more than 5 to 2 on Nasdaq. The broader S&P 500 soared 23 points to 2,163. Bitcoin gained $11 to $715.
